Drugs that contain Setmelanotide Acetate
1. Drug name - IMCIVREE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(5 years from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(5 years from now) | |
| CN101676298A | RHYTHM | Melanocortin Receptor Ligand |
Apr, 2014
(8 years ago) | |
| CN101257916B | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| CN103755786A | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| CN101257916A | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| CN103755786B | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| IN200904039P2 | RHYTHM | A Melanocortin-4 Selective Receptor Agonist Compound |
Jul, 2026
(3 years from now) | |
| IN290770B | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| IN290823B | RHYTHM | A Melanocortin-4 Selective Receptor Agonist Compound |
Jul, 2026
(3 years from now) | |
| IN200800208P2 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2286825A3 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2548568A2 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2548568B1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2286825B1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2286825A2 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP3354273A1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2548568A3 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP3354273B1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2236151B1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| EP2236151A1 | RHYTHM | Melanocortin Receptor Ligands |
Jul, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(11 years from now) | |
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 10MG/ML BASE (EQ 10MG/ML BASE) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.